Short answer
CERUS CORP (CERS) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$19,000
- +99.4% YoY · +99.7% QoQ
- EPS (diluted)
- $0.00
- +100.0% YoY · +100.0% QoQ
Source: XBRL data from the CERUS CORP (CERS) Q3 2025 10-Q on SEC EDGAR. USD.
CERUS CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product focus: platelet and plasma systems commercialized; red blood cell system remains in development
- RedeS enrollment completed in 2025; trial completion anticipated in second half of 2026
- Near-term headwinds: ongoing red blood cell development costs, regulatory uncertainty, tariffs, trade tensions, and potential funding constraints
Risk Factors
- Newly added risk: recent environmental-bacterium contamination after INTERCEPT treatment, linked to mishandling by blood-center customers
- Most material update: U.S. platelet adoption risk heightened by ongoing blood shortages and staffing constraints delaying implementation
- Regulatory risk: FDA has not granted INTERCEPT-treated platelets a seven-day storage claim, limiting labeled use beyond five days
- Operational risk: American Red Cross competing priorities prevent internal IFC production, increasing reliance on Cerus supply
- Market concentration risk: American Red Cross represents the largest single portion of U.S. blood collection demand
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CERUS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.